10 Most Promising Stocks with Highest Upside Potential
On June 16, Savita Subramanian, BofA Securities, joined CNBC's 'Power Lunch' to discuss the overall market environment and whether earnings momentum can continue.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 7,676,541 | $429,348,929 | +15% | 0.2% |
| 2. | Viking Global Andreas Halvorsen | 7,062,077 | $398,936,730 | +17% | 1.12% |
| 3. | Citadel Investment Group Ken Griffin | 4,512,634 | $254,918,695 | +231% | 0.04% |
| 4. | Vestal Point Capital Ryan Wilder | 3,575,000 | $201,951,750 | +20% | 5.65% |
| 5. | Millennium Management Israel Englander | 3,010,308 | $170,052,299 | -1% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | $314,468.75 | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | $70,955.37 | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | $930,759.69 | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | $3,503.36 | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | $11,924.48 | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $53.85 | 3,281 | $176,681.85 | 51,818 | 2026-05-07 | Filing | |
| $60.46 | 16,486 | $996,743.56 | 79,953 | 2026-03-11 | Filing | |
| $60.38 | 6,326 | $381,937.31 | 37,578 | 2026-02-26 | Filing | |
| $61.36 | 26,061 | $1,599,102.96 | 72,453 | 2026-02-26 | Filing | |
| $59.31 | 1,786 | $105,927.66 | 14,173 | 2025-05-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,696 | $497,585 | 0.41% | |
| 2. | 2,549 | $145,854 | 0.01% | |
| 3. | 461 | $26,378 | 0% | |
| 4. | 234 | $13 | 0% |
News See All
10 Most Undervalued Stocks to Buy and Hold for 2 Years
On May 27, Kathleen Entwistle, Managing Director & Private Wealth Advisor at Morgan Stanley Private Wealth Management, joined CNBC's 'Fast Money' to discuss buying opportunities in the current market.
8 Stocks That Could 10X by 2030
Could rising bond yields, along with economic and inflationary pressures, be spelling trouble or a correction for the equity market? That’s the big question at a time when equities have risen to all...
10 Best Low Priced Stocks to Buy for the Next 3 Years
On May 12, Chris Veronne of Strategas appeared on CNBC's 'Closing Bell Overtime' to share his technical take on the current market picture.
Evercore ISI Lifts PT on BioMarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best healthcare stocks to buy for the long term. Evercore ISI lifted the price target on BioMarin Pharmaceutical Inc.
10 Best Healthcare Stocks to Buy for the Long Term
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived, especially when compared...
Is BioMarin Pharmaceutical Inc. (BMRN) One of the Top Cheap Stocks to Buy With the Biggest Upside Potential?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top cheap stocks to buy with the biggest upside potential. BioMarin Pharmaceutical Inc.
Top 10 Cheap Stocks to Buy with Biggest Upside Potential
He was of the view that the risk/reward for stocks is still pretty good.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2026 Earnings Call Transcript
Operator: Good afternoon and welcome everyone to the BioMarin Pharmaceutical Inc. First Quarter 2026 Conference Call. Today's conference is being recorded.
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations
TheFly reported on March 16 that Wells Fargo maintained an Overweight rating on BMRN with a $75 price target.
Hedge Fund Resource Center